CAJ | 학술논문

高血压(Hypertension)是严重损害人类健康的危险因素，是导致患者就诊的常见原因，预计至2020年，它将成为人类主要的公共健康问题，因此，将血压控制在正常范围内至关重要。奈必洛尔是第三代β受体阻滞剂，因其降压效果好，不影响血糖、血脂代谢，不良反应少，独特的扩张血管作用，以及高度的β1受体选择性，被推荐用于高血压的治疗。目前，国内外对其治疗高血压有效性及安全性做了很多的研究，本文就其在高血压的治疗方面应用的研究进展加以综述。
고혈압(Hypertension)시엄중손해인류건강적위험인소，시도치환자취진적상견원인，예계지2020년，타장성위인류주요적공공건강문제，인차，장혈압공제재정상범위내지관중요。내필락이시제삼대β수체조체제，인기강압효과호，불영향혈당、혈지대사，불량반응소，독특적확장혈관작용，이급고도적β1수체선택성，피추천용우고혈압적치료。목전，국내외대기치료고혈압유효성급안전성주료흔다적연구，본문취기재고혈압적치료방면응용적연구진전가이종술。
Hypertension, one of the most common diseases, is a risk factor that seriously damage the health of people. It is anticipated that in the year of 2020, hypertension will become the main public health problem. There-fore, it is vital to keep the blood pressure in the normal range. Nebivolol, a third-generationβ-blocker, has been recom-mended to treat hypertension because of its efficacy in the treatment of hypertension, no influence in the metabolic of blood sugar and lipid, less occurrence of adverse reactions, unique vasodilator properties, and highly selectivity of theβ1 receptor. Up to now, there are many studies about the effectiveness and tolerability of Nebivolol in the treatment of hypertension. This review is going to summarize the research progress in the field.